Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have moderate to severe rheumatoid arthritis~* On methotrexate but inadequately controlled~* Subjects must not have active tuberculosis or an inadequately treated tuberculosis infection~* Subjects must use contraception~Exclusion Criteria:~* Subjects who have been previously treated with adalimumab or Tofacitinib~* Subjects with any current malignancy or a history of malignancy, with the exception of adequately treated or excised non metastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ.~* Subjects with specific laboratory test abnormalities~* Subjects with specific types of infections

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tofacitinib 5 mg twice daily with methotrexate (Type: EXPERIMENTAL): None
- Tofacitinib 5 mg twice daily monotherapy (Type: EXPERIMENTAL): None
- Adalimumab with methotrexate (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).